 |
|
Pharmacological Therapy in Progressive Supranuclear Palsy
K. Kompoliti, MD;
C. G. Goetz, MD;
Irene Litvan, MD;
K. Jellinger, MD;
M. Verny, MD
Arch Neurol. 1998;55:1099-1102.
Background To our knowledge, previous reports on drug treatment in progressive supranuclear palsy have not evaluated autopsy-confirmed cases.
Objective To evaluate pharmacological treatment responses from detailed clinical records in patients with autopsy-confirmed progressive supranuclear palsy.
Subjects and Methods We reviewed medical records for clinical presentation and pharmacological response in 12 patients with autopsy-confirmed progressive supranuclear palsy diagnosed using the National Institute of Neurological Disorders and Stroke pathologic criteria. For each drug class, exposure, global positive response, and specific positive response (parkinsonism, other movement disorders, or gaze dysfunction) were recorded.
Results Drug classes examined were dopaminergics (all patients), tricyclics (3 patients), methysergide maleate (3 patients), 5-hydroxytryptophan (2 patients), and anticholinergics and selective serotonin inhibitors (1 patient). Positive clinical response was detected in 7 of the patients receiving dopaminergic drugs and in 1 patient each receiving tricyclics, methysergide, and 5-hydroxytryptophan, respectively. None of the patients responded markedly however, and there was no persistent beneficial effect. Use of dopaminergic drugs most frequently improved parkinsonian features, but disabling adverse effects included orthostatic hypotension (6 patients), hallucinations and delusions (3 patients), gastrointestinal complaints (3 patients), and dizziness (1 patient). Only 1 patient developed dyskinesia.
Conclusion Use of antiparkinsonian medications and other neurotransmitter replacement therapies was largely ineffective and caused frequent adverse effects in this series of patients with autopsy-confirmed with progressive supranuclear palsy.
From the Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill (Drs Kompoliti and Goetz); Neuroepidemiology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Md (Dr Litvan); Ludwig Boltzmann Institute of Clinical Neurobiology, Vienna, Austria (Dr Jellinger); and Hôpital Charles Foix, Paris, France (Dr Verny).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A clinical rating scale for progressive supranuclear palsy
Golbe and Ohman-Strickland
Brain 2007;130:1552-1565.
ABSTRACT
| FULL TEXT
Progressive Supranuclear Palsy: Disease Profile and Rehabilitation Strategies
Zampieri and Di Fabio
ptjournal 2006;86:870-880.
FULL TEXT
Progression of gait, speech and swallowing deficits in progressive supranuclear palsy
Goetz et al.
Neurology 2003;60:917-922.
ABSTRACT
| FULL TEXT
Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy
Litvan et al.
Neurology 2001;57:467-473.
ABSTRACT
| FULL TEXT
|
